%0 Journal Article %A Ayse Ulgen %A Christopher Amos %T Quantitative Trait Loci on Chromosome 21 have Pleiotropic Effects on %FEV1 and Allergen Polysensitization; asthma related traits in the EGEA study %D 2021 %R 10.1101/2020.04.17.20069369 %J medRxiv %P 2020.04.17.20069369 %X To investigate whether the 21q21 region may contain a quantitative trait locus (QTL) with pleiotropic effect on % predicted FEV1 (forced expiratory volume in 1 second) and SPTQ (number of positive skin test responses to 11 allergens), in 295 EGEA families ascertained through asthmatic probands, we conducted a bivariate linkage analysis using two approaches:(1) a bivariate variance components (VC) analysis and (2) A combined principal components (CPC) analysis, with 13 microsatellites covering the whole chromosome 21. To identify the genetic variants associated with these traits, we performed family-based association analysis (FBAT) for the second principal component (PC2) using two microsatellites and 27 SNPs belonging to three candidate genes, located in the vicinity of the linkage peak. Univariate linkage analyses showed suggestive evidence of linkage to %FEV1 and SPTQ at two positions. Bivariate VC linkage analysis of these phenotypes led to an increase in linkage signals as compared to univariate analysis at the same positions. The peaks obtained by the CPC led to similar results as the full bivariate VC approach; evidence for linkage mainly coming from PC2. The strongest association signal, using single marker analysis for PC2, was obtained with D21S1252 (p=0.003 for global test; p=0.004 for allele 2 and p=0.001 for allele 11) and rs2834213 of IFNGR2 (p=0.003), these two loci being 3 Mb apart. Multi-marker analysis further strengthened this finding. These results indicate that at least two genetic factors may be involved in SPTQ and %FEV1 variability but further genotyping is needed to better understand these findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by INSERM, the French Ministry of Higher Education and Research, University of Evry, Fondation pour la Recherche Médicale (ACE20061209064) and the French National Agency for Research (ANR 05-SEST-020-02/05-9-97) and ANR 06-CEBS- 029-2).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and quality management: Inserm ex-U155 (Egea1): J Hochez; Inserm U 780, Villejuif: N Le Moual, C Ravault; Inserm U 794: N Chateigner; Grenoble: J Ferran. %U https://www.medrxiv.org/content/medrxiv/early/2021/04/21/2020.04.17.20069369.full.pdf